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Abstract
Knockout (KO) mice that lack the dopamine transporter (SL6A3; DAT) display
increased locomotion that can be attenuated, under some circumstances, by
administration of drugs that normally produce psychostimulant-like effects, such as
amphetamine and methylphenidate. These results have led to suggestions that DAT
KOmicemaymodel features of attention deficit hyperactivity disorder (ADHD) and that
these drugs may act upon serotonin (5-HT) systems to produce these unusual
locomotor decreasing effects. Evidence from patterns of brain expression and initial
pharmacologic studies led us to use genetic and pharmacologic approaches to
examine the influence of altered 5-HT1B receptor activity on hyperactivity in DAT KO
mice. Heterozygous 5-HT1B KO and pharmacologic 5-HT1B antagonism both
attenuated locomotor hyperactivity in DAT KO mice. Furthermore, DAT KO mice with
reduced, but not eliminated, 5-HT1B receptor expression regained cocaine-stimulated
locomotion, which was absent in DAT KO mice with normal levels of 5-HT1B receptor
expression. Further experiments demonstrated that the degree of habituation to the
testing apparatus determined whether cocaine had no effect on locomotion in DAT KO
or reduced locomotion, helping to resolve differences among prior reports. These
findings of complementation of the locomotor effects of DAT KO by reducing 5-HT1B
receptor activity underscore roles for interactions between specific 5-HT receptors and
dopamine (DA) systems in basal and cocaine-stimulated locomotion and support
evaluation of 5-HT1B antagonists as potential, non-stimulant ADHD therapeutics.
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Introduction
Dopamine (DA) systems have long been implicated in the control of basal [1, 2]
and stimulant-induced locomotion [3–5]. Activity of the dopamine transporter
(SLC6A3, DAT) is a major determinant of DA compartmentalization, modulating
the dynamic temporal profiles of intracellular, synaptic, and extrasynaptic DA
levels [6, 7]. The elimination of DAT expression in DAT KO mice leads to
profound changes in DA release dynamics [8], elevated basal levels of extracellular
DA [8, 9] and profound locomotor hyperactivity [10, 11]. Cocaine-induced
locomotion is also eliminated in DAT KO mice [10, 12]. Indeed, under some
conditions, decreased locomotion is observed in DAT KO mice after adminis-
tration of cocaine or other psychostimulant drugs [13], mimicking the therapeutic
effects that stimulants provide for many individuals with attention deficit
hyperactivity disorder (ADHD) [14, 15]. DAT KO mice also have deficits in pre-
pulse inhibition of acoustic startle (PPI) [16] that are reversed by psychostimulant
drugs [17]. Similar to the effects of these drugs on locomotion, although they
improve PPI in DAT KO mice, they produce impairments in wildtype (WT) mice.
This pattern of effects of psychostimulant drugs on locomotor behavior and
PPI have led to suggestions that DAT KO mice may serve as a model of ADHD
[18, 19]. Effects of psychostimulant drugs on serotonin (5-HT) function were
initially suggested to be involved in the amelioration of hyperactivity in DAT KO
mice by psychostimulant drugs based on the effects of other serotonergic agents in
this model [13]. 5-HT systems, via interactions with DA systems, have been
implicated in modulation of both basal and psychostimulant-induced locomotion
for some time [20–22]. 5-HT systems that act through 5-HT1B receptors are
especially promising candidates to contribute to these direct and interactive
influences on locomotor behavior based upon their placement in this circuitry
[23–25]. High levels of 5-HT1B receptors are expressed by striatonigral neurons
that provide direct pathway feedback to ventral midbrain dopaminergic neurons
that are heavily implicated in motor control [26–29]. 5-HT can facilitate DA
release [30, 31] in ways that involve 5-HT1B receptors [32], although other 5-HT
receptor subtypes also modulate DA release and neuronal activity [33–35].
Combined deletion of DAT and the serotonin transporter (SERT) to produce
DAT/SERT double KO mice results in even higher basal locomotion than that
displayed by DAT deletion alone and 5-HT1B receptor levels are reduced in the
substantia nigra of these mice [11]. 5-HT1B receptor KO mice display increased
locomotor responses to cocaine [36], while their levels of basal locomotion are
similar to those of wildtype (WT) mice [37, 38].
To elaborate further the role of 5-HT1B receptors in locomotor behavior, and in
the effects of DAT KO on locomotor behavior, genetic and pharmacologic
approaches were used in the present experiments. There was substantial
convergence between the results from studies of lifelong deletion of half of the
normal quantity of 5-HT1B receptors and acute blockade of 5-HT1B receptors in
these experiments. Furthermore, examination of basal and cocaine-stimulated
locomotor activity after both long and short periods of habituation identified this
DAT/5-HT1B Complementation
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factor, which differed in previous studies in DAT KO mice, as the critical factor
determining whether reductions in locomotion were observed after cocaine
treatment in DAT KO mice. The implications of the prominent role for 5-HT1B
receptors in serotonin-dopamine interactions in DAT KO mice identified in these
experiments is considered for the potential to develop non-psychostimulant
therapeutics the treatment of ADHD.
Results
Experiment 1: Basal and Cocaine-induced Locomotor Activity after
an Extended Period of Habituation
During the three hour period of habituation prior to cocaine administration
locomotor activity was greater in DAT 2/2 mice than in DAT +/2 or DAT +/+
mice (Fig. 1; DAT GENOTYPE: F [2, 81]511.4, p,0.0001). In combined
knockout mice, the effect of DAT KO depended strikingly on 5-HT1B genotype.
The basal hyperactivity found in DAT 2/25-HT1B +/+ mice was reduced sharply,
to nearly normal levels, in DAT 2/25-HT1B +/2 mice that have reduced 5-HT1B
receptor expression. This effect appears to require some 5-HT1B expression,
however, since the genetically complementing influence of reducing 5-HT1B
expression was not observed in mice with complete elimination of both DAT and
5-HT1B. Locomotion in DAT2/25-HT1B2/2mice was thus similar to the levels
of hyperactivity noted in the DAT 2/25-HT1B +/+ mice.
There were no significant differences in between-session habituation between
mice of the differing genotypes. Differences in basal locomotion observed in the
first session continued to be observed in later habituation sessions that preceded
dose-response testing later in this experiment. Locomotor activity scores that were
summed for subsequent habituation sessions revealed group effects that were
virtually identical to the locomotion observed during the initial habituation
session (Fig. 2). Data in Fig. 2 documents the persistence of the lower activity of
DAT 2/25-HT1B +/2 mice when compared to either DAT 2/25-HT1B +/+ or
DAT 2/25-HT1B 2/2 mice. The main effect of DAT GENOTYPE was highly
significant (F [2, 81]514.9, p,0.0001). Post hoc examination of the DAT
GENOTYPE effect demonstrated that these effects were dependent on the 5-HT1B
receptor genotype. Scheffe’s comparisons for each DAT 2/2 genotype group
versus DAT +/+5-HT1B +/+ mice found significantly greater locomotion in DAT
2/25-HT1B +/+ mice and DAT 2/25-HT1B 2/2 mice, but not in DAT 2/25-
HT1B +/2 mice, for all habituation sessions compared to DAT +/+5-HT1B +/+
mice (Fig. 2). By contrast, due to the inverse 5-HT1B gene dose-response
relationship, neither the main effect of 5-HT1B GENOTYPE (F [2, 81]51.8, ns)
nor the DAT GENOTYPE65-HT1B GENOTYPE interaction (F [4, 81]51.3, ns)
reached statistical significance.
Locomotor responses to saline or cocaine injection are presented in Fig. 3. The
differences between locomotion following injection and the summed locomotion
in the two hours of habituation prior to drug injection are represented to correct
DAT/5-HT1B Complementation
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for differences in baseline activity. Saline administration did not increase
locomotion. Activity of mice of most genotypes, including DAT 2/25-HT1B +/2
mice, was minimal after saline injections. By contrast, the locomotor activity of
DAT 2/25-HT1B +/+ and DAT 2/25-HT1B 2/2 mice continued to decrease
after saline injections; these mice appear to experience continued habituation
from the higher levels of locomotor activity that they display at the beginning of
the test period. As previously reported [12], DAT 2/25-HT1B +/+ mice exhibited
no locomotor stimulant responses to cocaine. These differences from the
substantial increases observed in DAT +/+5-HT1B +/+ and DAT +/25-HT1B +/+
mice resulted in an overall significant effect of DAT GENOTYPE (F [2, 81]514.9,
p,0.0001). Failure to observe increases in DAT 2/25-HT1B +/+ mice did not
Fig. 1. Experiment 1: Time-course of baseline locomotor activity in combined DAT/5-HT1B KO mice:
long habituation session. Time-course of locomotor activity during the first habituation session in DAT/5-
HT1B KO mice (9 genotypes: DAT +/+5-HT1B +/+, DAT 2/25-HT1B +/+, DAT +/+5-HT1B 2/2, DAT +/25-
HT1B 2/2, DAT 2/25-HT1B +/2, DAT 2/25-HT1B 2/2) expressed in terms of total distance traveled. Data
are represented as mean ¡ SEM.
doi:10.1371/journal.pone.0115009.g001
Fig. 2. Experiment 1: Baseline locomotor activity in well habituated combined DAT/5-HT1B KO mice.
Total locomotor activity in DAT/5-HT1B KO mice (9 genotypes: DAT +/+5-HT1B +/+, DAT 2/25-HT1B +/+,
DAT +/+5-HT1B 2/2, DAT +/25-HT1B 2/2, DAT 2/25-HT1B +/2, DAT 2/25-HT1B 2/2) expressed in
terms of summed distance traveled during all of the 4 habituation sessions prior to drug (5, 10 and 20 mg/kg
IP cocaine; C5, C10 and C20 respectively) or saline (SAL) injections. *Significant difference from DAT +/+5-
HT1B +/+ mice based on Scheffe’s post hoc comparison (p,0.05). Data are represented as mean ¡ SEM.
doi:10.1371/journal.pone.0115009.g002
DAT/5-HT1B Complementation
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appear to be due to ceiling effects. Habituation had reduced locomotion to
approximately half of initial levels when cocaine was administered (see Fig. 1).
Cocaine administration significantly increased locomotion, with maximal
increases at 20 mg/kg (Fig. 3; DOSE: F [3,243]536.6, p,0.0001), although
increases were not apparent in mice of all genotypes. Post hoc evaluations of the
effect of DOSE (by 1-way ANOVA) in each genotype revealed a significant effect
of DOSE in DAT 2/25-HT1B +/2 mice that was not observed in DAT 2/25-
HT1B +/+ or DAT 2/25-HT1B 2/2 mice. While deletion of a single copy of the
5-HT1B receptor gene in DAT 2/25-HT1B +/2 mice restored the ability of
cocaine to increase locomotion, some 5-HT1B expression appears necessary to
normalize responses to cocaine in DAT 2/2 mice. Significant effects of cocaine
DOSE were observed in mice of all other genotypes (p,0.01). The interaction of
cocaine DOSE and DAT GENOTYPE was not significant in the ANOVA,
however.
Experiment 2: Cocaine-induced Locomotor Activity after a Brief
Period of Habituation
During 30 minute short habituation sessions, DAT 2/2 mice were significantly
more active than mice of all other genotypes (DAT GENOTYPE: F [2,97]530.6,
p,0.0001; Fig. 4A). During this shorter habituation period there was no
significant complementation observed between DAT and 5-HT1B genotypes (DAT
GENOTYPE65-HT1B GENOTYPE: F [4,97]51.9, NS), although the same overall
pattern was observed as in Experiment 1. Baseline differences in locomotor
activity did not equalize over 30 min habituation periods. Effects of cocaine on
locomotion were thus evaluated as the difference between activity after cocaine
administration and activity after saline administration (Fig. 4B).
There was a significant effect of DAT GENOTYPE on the locomotor stimulant
effects of cocaine (Fig. 4B; F [2,97]511.4, p,0.0001). However, there were no
Fig. 3. Experiment 1: Cocaine-induced locomotion in well habituated DAT/5-HT1B KO mice. Cocaine-
induced locomotor activity in DAT/5-HT1B KO mice is expressed as absolute difference s from baseline,
preinjection values. Post hoc analysis by 1 way ANOVA for COCAINE concentration revealed significant
effects of cocaine for all genotypes except DAT 2/25-HT1B +/+ and DAT 2/25-HT1B 2/2. Data are
represented as mean ¡ SEM.
doi:10.1371/journal.pone.0115009.g003
DAT/5-HT1B Complementation
PLOS ONE | DOI:10.1371/journal.pone.0115009 December 16, 2014 5 / 20
significant effects of either 5-HT1B GENOTYPE (F [2,97]50.1, ns) nor interaction
between DAT GENOTYPE and 5-HT1B GENOTYPE (F [4,97]50.4, ns). The
significant effect of DAT GENOTYPE reflects the large increases in locomotion
produced by cocaine administration after this short period of habituation period
in DAT +/+ mice and DAT +/2 mice, but not DAT 2/2 mice of any 5-HT1B
genotype. Under these experimental conditions cocaine reduced locomotion
below levels observed after saline injection alone in DAT 2/2 mice. 5-HT1B
genotype failed to produce any significant effects on locomotor responses to
cocaine administered after this short period of habituation.
Analyses of the time course of locomotor activity for each genotype separately
(Fig. 5) revealed increased locomotor activity after cocaine in all DAT +/+ and
DAT +/2 genotypes, regardless of 5-HT1B genotype. There were significant
DRUG6TIME interactions (p,0.01) for all DAT +/+ and DAT +/2 genotypes.
For DAT 2/2 genotypes cocaine decreased activity. This effect achieved
significance in DAT 2/25-HT1B +/2 and DAT 2/25-HT1B 2/2 mice, reflected
by significant DRUG6TIME interactions (p,0.01), but not in DAT 2/25-HT1B
+/+ mice. 5-HT1B KO thus appears to slightly enhance the locomotion-reducing
effects when cocaine is administered after a short period of habituation.
Fig. 4. Experiment 2: Locomotor activity in combined DAT/5-HT1B KO mice: short habituation
sessions. (A) Time-course of locomotor activity during the first habituation session in DAT/5-HT1B KO mice
(9 genotypes: DAT +/+5-HT1B +/+, DAT 2/25-HT1B +/+, DAT +/+5-HT1B 2/2, DAT +/25-HT1B 2/2, DAT
2/25-HT1B +/2, DAT 2/25-HT1B 2/2) expressed in terms of total distance traveled. (B) Cocaine-induced
locomotor activity in DAT/5-HT1B KO mice expressed as absolute difference from saline (total activity after
cocaine injection – total activity after saline injection). Data are represented as mean ¡ SEM.
doi:10.1371/journal.pone.0115009.g004
DAT/5-HT1B Complementation
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Experiment 3: The effects of the 5-HT antagonist SB 224289 on
locomotor activity in DAT 2/2 and DAT +/+ mice
In this experiment locomotor activity was again elevated in DAT 2/2 mice
compared to DAT +/+ mice (Fig. 6; DAT GENOTYPE: F [1, 18]530.6,
p,0.0001). The high dose of SB 224289 significantly reduced locomotor activity
in the hyperactive DAT 2/2 mice (DRUG: F [3, 54]54.0, p,0.02) but not in
DAT +/+ mice. There was thus a significant GENOTYPE6DRUG6TIME
interaction (F [15, 270]52.2, p,0.01). Post hoc comparisons of the effect of SB
224289 in each genotype separately confirmed these observations. SB 224289 had
no effect on locomotor activity in DAT +/+ mice (DOSE: F [3, 27]50.5, ns;
DOSE6TIME: F [15, 135]51.1, ns), but the 5-HT1B antagonist significantly
reduced activity in DAT 2/2 mice (DOSE: F [3, 27]53.5, p,0.03;
DOSE6TIME: F [15, 135]52.3, p,0.01).
Fig. 5. Experiment 2: Time-course of locomotor activity in DAT/5-HT1B KO mice, short habituation sessions. Time-course of saline and cocaine-
induced locomotor activity in DAT/5-HT1B KO mice, represented separately for each genotype. Cocaine increased locomotion in all DAT +/+ and DAT +/2
genotypes (p,0.01), and reduced locomotion in all DAT 2/2 genotypes (p,0.01) except DAT 2/25-HT1B, which was confirmed by individual ANOVA
comparing saline and cocaine locomotion for each genotype. Data are represented as mean ¡ SEM.
doi:10.1371/journal.pone.0115009.g005
DAT/5-HT1B Complementation
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Discussion
The present data provide striking evidence that: 1) either chronic genetic or acute
pharmacologic reduction in 5-HT1B receptor function can reduce locomotor
impairments in DAT KO mice; 2) cocaine-induced locomotor activation can be
obtained in the absence of DAT when 5-HT1B receptor function is reduced; and 3)
psychostimulant drugs can decrease locomotion in DAT KO mice under
conditions in which only modest habituation occurs prior to drug administration.
The current data confirm and extend previous findings of: a) locomotor
hyperactivity and elimination of cocaine-stimulated locomotion in DAT knock-
out mice [10, 12], and b) cocaine-induced reductions in locomotor activity when
administered to mice after short habituation periods [13]. We discuss these
observations in the light of evidence for involvement of DAT and different 5-HT1B
receptor subpopulations in basal- and cocaine-stimulated locomotion, and of
their implications for understanding this model of ADHD.
Genetic complementation and pharmacological confirmation
DAT deletion produces baseline hyperactivity but prevents further cocaine-
induced increases in activity. We show here that the effects of DAT deletion on
basal and cocaine-induced locomotion were reversed when a heterozygous 5-
HT1B receptor KO was combined with a homozygous DAT deletion. This
evidence for classical genetic complementation, reversal of influences of one
genetic change when another is added, provides strong evidence for the
importance of 5-HT systems that involve 5-HT1B receptors in the locomotor
phenotypes observed in DAT KO mice. The pharmacological results of acute
administration of the 5-HT1B antagonist SB 224289 buttress these genetic
findings, and make it less likely that this result depends on adaptations to chronic
5-HT1B depletions in the heterozygous KO mice.
Fig. 6. Experiment 3: The effects of the 5-HT antagonist SB 224289 on locomotor activity in DAT KO
and WT mice. Time-course locomotor activity in DAT 2/2 and DAT +/+ mice after injection with 0, 5, 10, or
20 mg/kg SB 224289. Data are represented as mean ¡ the SEM.
doi:10.1371/journal.pone.0115009.g006
DAT/5-HT1B Complementation
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5-HT1B gene dose response relationship and comparisons
previous findings
By contrast to the results in heterozygous 5-HT1B KO mice, complete deletion of
the 5-HT1B receptor in homozygous 5-HT1B KO mice does not alter the
locomotor effects of DAT gene deletion. These observations support an inverse
gene-dose relationship and a requirement for some level of 5-HT1B receptor
function to normalize locomotor behavior in homozygous DAT 2/2 mice. This
complex gene-dose relationship for homozygous DAT KO mice appears to be
accompanied by differences in dose-response relationships for 5-HT1B antagonists
in modulating locomotion in different genetic and behavioral settings. In the
present work, mice with wildtype DAT genetic backgrounds displayed no
significant differences in locomotion after either genetic 5-HT1B manipulations or
5-HT1B antagonist treatment. Acute 5-HT1B antagonist treatment also exerted
only minimal effects on locomotion in WT mice in another study, although 5-
HT1B antagonism restored methamphetamine-induced locomotor sensitization in
serotonin transporter (SLC6A4; SERT) KO mice in that study [39]. These
divergent effects of 5-HT1B manipulations on locomotor activity in DAT KO and
SERT KO mice, compared to WT mice, bear some similarity to the divergent
effects on reinforcement in animals with different experimental histories. 5-HT1B
agonists have been shown to enhance cocaine reinforcement but decrease cocaine-
seeking in a reinstatement model, when they are administered following different
periods of cocaine self-administration and withdrawal [40, 41].
An interesting point here is the lack of effect of 5-HT1B manipulations alone.
Our results differ from those reported by Castanon et al (2000), who found that
5-HT1B KO increased cocaine-induced locomotion while 5-HT1B antagonists
reduced cocaine-induced locomotion. These differences might be due to
differences in the state of the mice tested, since increases in basal or stimulant-
induced locomotor activity are likely to depend on dopaminergic cell firing rates
that can be altered substantially by habituation to the environment [42], as was
shown in the present experiments when habituation prior to drug injection was
specifically manipulated. Genetic background might also play a role in these
differences. Castanon et al (2000) used an inbred 129/Sv 5-HT1B KO strain for the
genetic study, but C57Bl/6J mice for the pharmacological study. Genetic variation
across strains, or genetic manipulations that cause perturbations in function
throughout this circuitry such as DAT and SERT, would appear to alter the
consequences of 5-HT1B receptor manipulations.
Adaptation in KO mice versus acute differences in
psychostimulant responses
Studies of the adaptations to the chronic loss of DAT function in DAT KO mice
have centered on DA receptor dynamics [8, 10, 43–45]. Our current results should
add impetus to studies of 5-HT systems and DA-5-HT interactions in these
animals as well [9, 13, 43]. We have previously reported reduced 5-HT1B receptor
expression in mice with combined DAT 2/2 SERT 2/2 gene deletions [11], but
DAT/5-HT1B Complementation
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have not identified changes in brain 5-HT1B mRNA expression in DAT KO mice
(Li, Hall and Uhl, unpublished findings). More subtle region- or cell-specific
changes are still possible, as are adaptations at other (e.g. circuitry) levels (see
below).
Roles for adaptations to the removal of 5-HT1B receptors also remain possible,
although the fit between data from 5-HT1B receptor knockdown (e.g.
heterozygous KO mice) and acute antagonist treatments is consistent with direct
roles of 5-HT1B systems/acute alterations in many of the effects observed here.
Brain changes reported in homozygous 5-HT1B KO mice do include reduced 5-
HT levels, increased DA levels, and enhanced cocaine-induced DA release in
nucleus accumbens [46]; reduced striatal SERT binding [47]; reductions in 5-
HT2C receptor function [48]; reduced cocaine-induced c-fos elevation [49]; and
changes in several other receptor systems [50]. The degree to which these changes
occur in heterozygous 5-HT1B KO mice, if at all, is not known however, which
adds to the likelihood that the effects of heterozygous 5-HT1B deletion are the
result of the reduced 5-HT1B receptor numbers, not other chronic adaptations.
The gene-dose dependence of the results that we report here, and their
convergence with the results of acute pharmacological interventions, both focus
attention on mechanisms that require at least some 5-HT1B receptors, and away
from mechanisms that are engaged by the total absence of 5-HT1B receptors.
Observations that mice without any functional copies of either DAT or 5-HT1B
lack any significant cocaine-induced locomotion support the idea that normal 5-
HT1B mechanisms are involved in cocaine-induced locomotor stimulation in
DAT KO mice and mechanisms that reduce locomotion in WT mice.
Dopamine, serotonin and locomotor control
DA systems are widely implicated in locomotor control by data from DA lesion,
antagonist and structure-activity studies [51–56]. Initial results in DAT KO mice
supported the longstanding view that DA is the primary mediator of locomotor
behavior and that cocaine is a locomotor stimulant due to its ability to elevate DA
levels by blocking DAT. Current results demonstrating restoration of cocaine-
induced locomotion in the absence of DAT in DAT 2/25-HT1B +/2 mice add to
other evidence that this view is oversimplified. Support for 5-HT1B receptors as
plausible sites for serotonergic effects on basal- and cocaine-modulated locomotor
activity comes from increased locomotion induced by the 5-HT1B receptor agonist
RU24969 [57] that can be blocked by the 5-HT1B receptor antagonist GR127935
[58] and 5-HT1B agonist treatment can potentiate nucleus accumbens dopamine
release in wildtype mice [59]. This pharmacological data alone might suggest that
5-HT1B receptors might have a role in ADHD.
Relevance to ADHD and ADHD symptomatology
DAT KO mice have been proposed to constitute an animal model of ADHD based
on the behavioral phenotypes observed in these mice and responses to drugs that
DAT/5-HT1B Complementation
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treat ADHD [13, 18]. This is consistent with transmission disequilibrium studies
that have associated human DAT genomic markers with ADHD in several, though
not all, clinical samples [60–63], although certainly none of those studies
identified a homozygous DAT KO in humans. Nonetheless, the decreased
locomotion noted in stimulant-treated DAT2/2mice under some circumstances
[13] has been suggested to parallel the ‘‘calming’’ effects of psychostimulants in
hyperactive children [14, 15]. The dependence of these effects in DAT 2/2 mice
on the degree of environmental stimulation in the current habituation studies is
consistent with reports in ADHD as well. Similar to these effects on DAT
hyperactivity, while administration of psychostimulant drugs to WT mice impairs
PPI, the deficits in PPI found in DAT KO mice are reversed by administration of
psychostimulant drugs that treat ADHD [17], the selective norepinephrine
reuptake blocker nisoxetine [17], and nicotine [64]. Much of this data is
consistent with the rate dependency theory of drug action in ADHD [65], which
has gained support from both clinical and brain imagining studies [66, 67].
Genetic studies in humans have associated the htr1B gene with ADHD in some
studies [68–71]. Such associations have not been found in all studies, but
suggestions of gene-gene interactions for ADHD susceptibility and parent of
origin effects [72] may account for some of these negative findings. Furthermore,
those authors suggested that epigenetic regulation of htr1B may also be involved.
That expression of the 5-HT1B receptor may affect ADHD is also suggested by
observations that genetic differences in the regulation of htr1B gene expression by
the microRNA miR96 are also associated with ADHD [73]. It remains to be seen
how genetic differences in this gene may interact with other genetic, or non-
genetic, differences in DAT function in humans. The present results certainly
suggest that this possibility should be investigated.
Potential circuitry underlying DAT-5HT1B interactions in DAT KO
mice
Circuits connecting midbrain to striatum include ventral midbrain dopaminergic
neurons that project to striatum, accumbens and cortex that receive reciprocal
direct pathway inputs from striatofugal fibers [24]. There are substantial
serotonergic inputs to these regions, including high concentrations of 5-HT1B
receptors on direct pathway/striatofugal connections from striatum to substantia
nigra and ventral tegmental area neurons [23, 25]. Although it is not possible to
exclude roles for other 5-HT1B receptor populations based on the present results,
it is tempting to focus on the direct pathway for explanations for many of the
effects of reduced 5-HT1B expression in DAT KO mice. 5-HT1B receptors in the
prefrontal cortex certainly modulate other behaviors [74], so it is possible that
receptors in that brain region influence behavior in DAT KO mice, but the
preponderance of evidence for 5-HT1B influences on locomotion involve
receptors in other brain regions. It thus appears most likely that the locus of 5-
HT1B effects is likely to be downstream from altered corticostriatal projections in
DAT KO mice [75].
DAT/5-HT1B Complementation
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Accumulating evidence in DAT KO mice has indicated that the prefrontal
cortex is the locus of psychostimulant drug effects in this model. Because of
differences in the distribution of DAT in DA terminal regions, the consequences
of DAT deletion on release dynamics in these regions are quite different. This can
be observed in terms of the profound effect of DAT KO on basal DA levels in the
striatum but rather minimal effects in the prefrontal cortex [9]. This imbalance in
DA levels appears to be further associated with alterations in corticostriatal
afferents and downstream circuitry [75, 76]. Subtle cognitive deficits have been
found in DAT KO mice that are associated with changes in brain derived
neurotrophic factor in the prefrontal cortex [77]. A potential model of aspects of
impaired decision-making in ADHD, the cliff avoidance reaction, is also impaired
in DAT KO mice and these deficits can also be reversed by drugs that treat ADHD
[78]. One consequence of these changes is the impairment of PPI in these mice
[16], which is ameliorated by administration of psychostimulant drugs or selective
norepinephrine transporter (NET) blockers [17], the later finding suggesting that
psychostimulant drugs produce these actions by blocking NET. Interestingly, in
manner similar to effects of psychostimulants on locomotor activity, although
psychostimulants normalize PPI in DAT KO mice, they produce impairments in
wildtype mice. Furthermore, the locus of these effects is in the prefrontal cortex
based on intracerebral injection experiments [75]. Nicotine, used as a form of self-
treatment for attentional deficits in ADHD [79], also acts in the prefrontal cortex
to ameliorate PPI deficits in DAT KO mice [64]. Although the role of 5-HT1B
receptors has not been specifically investigated in DAT KO mice using the PPI
model, serotonergic mechanisms were suggested to be important in the
amelioration of hyperactivity in DAT KO mice by psychostimulants [13], as well
as in the mechanism of action of nicotine in ameliorating PPI deficits [64]. This
certainly warrants further investigation.
Roles for behavioral state
Previous studies in two strains of DAT KO mice produced separately in different
laboratories found that DAT KO can eliminate the locomotor stimulant effects of
cocaine [10–12], but also that cocaine can reduce locomotor activity in DAT KO
mice [13]. The major difference in this later study from the previous studies
appeared to be the period of habituation prior to drug injection. Experiments 1
and 2 therefore confirm both types of psychostimulant effects in the same strain of
DAT KO mice under similar experimental conditions: elimination of cocaine-
induced increase in locomotor activity in Experiment 1 and cocaine-induced
reductions in locomotion in Experiment 2. 5-HT1B gene deletion thus has effects
on basal and cocaine-stimulated locomotion that depend on DAT genotype and
on the degree of habituation to the testing environment. Constitutive 5-HT1B
deletion alone does not affect basal or cocaine-stimulated locomotion in DAT +/+
mice under the conditions used here. Furthermore, in Experiment 3 the effect of
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the 5-HT1B antagonist SB 224289 on locomotion was observed only in DAT 2/2,
and not in DAT +/+ mice. Taken together with effects of habituation (comparing
Experiments 1 and 2), we can conclude that 5-HT1B manipulations alter
locomotion most prominently under conditions of high locomotor activity, e.g.
with little habituation to the environment, or under conditions that otherwise
elevate locomotion, such as DAT deletion. As discussed above, other data
supports the idea that 5-HT1B manipulations can increase or decrease DA
mediated behavior under different conditions. Interestingly, it has also been
reported 5-HT1B agonists have biphasic effects on locomotion at different time
periods after withdrawal from chronic cocaine self-administration [80].
Conclusions
Observations that deletion of one copy of the 5-HT1B receptor gene restores
cocaine-induced locomotion in DAT 2/2 mice appears to rule out the simplest
form of the ‘‘DAT is it’’ hypothesis of cocaine-induced locomotion, just as finding
at least some retained cocaine reward in DAT KO mice ruled out the simple ‘‘DAT
is it’’ hypothesis of cocaine reinforcement [12, 81]. This genetic complementation
also supports at least some 5-HT1B-dependence of the development or expression
of some of the adaptive processes found in DAT KO mice, including those that
contribute to basal hyperactivity and to elimination of cocaine-stimulated
locomotion [10–12]. The influence of 5-HT receptor activation on DA function is
quite complex however, as indicated by the observation that 5-HT1B antagonist
treatment reduces locomotor sensitization to methamphetamine in WT mice but
restores sensitization in SERT KO mice [39]. This finding, among others, makes it
apparent that different 5-HT1B receptor populations can influence locomotor
behavior in different ways, and that the overall effect of 5-HT1B receptor agonism
or antagonism can be quite different under different circumstances.
The current data document how adaptations to lifelong absence of DAT can
involve non-dopaminergic systems in addition to the well-documented alterations
in dopaminergic parameters in DAT KO mice [8, 45]. Some of the adaptations to
shorter-term blockade of DAT by psychostimulants may parallel these
consequences of lifelong DAT deletion. Further studies that elucidate the roles of
5-HT1B autoreceptors located on raphe´ neurons, 5-HT1B receptors on
striatonigral cells, and 5-HT1B receptors located on other neurons in locomotor
circuits will clarify the multiple roles of 5-HT1B receptors in these different states.
Such studies have helped to identify particular 5-HT1B receptor populations
involved in different aspects of cocaine reinforcement and reinstatement [82]. The
current results thus seem to warrant increased consideration of 5-HT1B-
dependent mechanisms in normal locomotor control, locomotor modulation by
acute psychostimulant administration and variations in motor control due to
genetic and/or developmental variations in dopaminergic systems that may be
associated with ADHD.
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Materials and Methods
Subjects
DAT [12] and 5-HT1B receptor [83] KO mice were used to generate combined
DAT/5-HT1B KO mice by crosses of these lines to produce double heterozygous
KO mice in the F1 generation, and subsequent double heterozygous crosses that
resulted in all combinations of genotypes, including double homozygous KO
mice, beginning in the F2 generation. Mice were of a mixed genetic background,
C57BL/6J and 129/Sv, derived from each of the original KO strains. Mice were
tested at 12–18 weeks of age. The number of subjects per condition in each
particular experiment is listed below. Each genotype group consisted of equal
numbers of males and female mice, but this was not included in the analysis and
the group sizes are not listed separately by sex below. The majority of mice used in
these studies were products of double heterozygous crosses, however, because of
the rarity of double KO and double WT mice under these conditions, and the
increased mortality that has been noted in DAT KO mice previously, an
additional breeding strategy was used to produce a sufficient number of subjects;
this involved crosses of DAT+/25-HT1B +/+, DAT +/+5-HT1B +/2, and DAT +/
25-HT1B 2/2 mice. All of these breeder mice were derived from double
heterozygous crosses. Crosses of all genotypes produced similar initial litter sizes
and expected genotype distributions (given the increased DAT mortality). Those
crosses that produced higher numbers of DAT 2/2 mice than double
heterozygote crosses did have greater postnatal and post-weaning mortality which
was solely attributable to the loss of DAT 2/2 mice. No gross abnormalities or
behavioral phenotypes were obvious in double KO mice beyond those that have
already been reported for the single KO mice. All experiments were conducted in
accordance with National Institutes of Health (USA) guidelines governing the use
of animals in experimental research under protocols approved by the National
Institute on Drug Abuse (USA) Intramural Research Program Animal Care and
Use Committee (Protocol number 10-MNRB-07).
Genotyping
Mice were genotyped by PCR for DAT and 5-HT1B genotypes using two internal
primers, one targeted at the NEO portion of the transgenic construct (KO primer)
and one targeted at the WT gene (WT primer), and one external primer for each
gene. PCR using Takara ExTaq or e2Tak DNA polymerase (Takara, Japan) was
performed on tail DNA eluted after digestion overnight in Protease K. For DAT
genotyping the forward primer (59 GAC TTG CTG TGA CCT GGC TAG GAA C
39) and the WT primer (59 GCC TTG AGC TCT TAT CGG GCC TCC 39)
produced a 640 bp band, while the forward primer and the KO primer (59 GCC
TCT GTC CGC AGT TCA TTC AG 39) produced a 900 bp band. For 5-HT1B
receptor genotyping the forward primer (59 GAC TTG GTT CAC GTA CAC AG
39) and the WT primer (59 CCC ATC AGC ACC ATG TAC AC 39) produced a
560 bp band, while the forward primer and the KO primer (59 CTT CTA TCG
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CCT TCT TGA CG 39) produced a 680 bp band. The PCR products were
separated and visualized using gel electrophoresis for determination of individual
genotypes.
Locomotor Activity Testing
Locomotor activity was assessed in Plexiglas boxes (36618618 cm) using an
automated Optovarimax system (Columbus Instruments, Columbus, OH, USA).
The total distance traveled during each time bin was calculated from infrared
beam-breaks by ATS software that localized the subject’s position in the apparatus
(Columbus Instruments, Columbus, OH, USA). The locomotor activity monitors
were placed in sound-attenuating chambers and all locomotor activity was
assessed under dark conditions between 10 AM and 4 PM. The methods used to
examine locomotor behavior are generally similar to our previous publications
with DAT KO and DAT/SERT KO mice [11, 12]. Habituation, duration of testing
and timing of drug injections was different for each experiment. These details are
described below.
Experiment 1: Basal and Cocaine-induced Locomotor Activity after
an Extended Period of Habituation
Using a within subjects design, mice from all 9 DAT/5-HT1B double KO genotype
combinations (n59–11 per genotype) were placed in the locomotor test chambers
and allowed to habituate for 3 hours prior to injection with cocaine (0.0, 5.0, 10.0
and 20.0 mg/kg s.c.). At least 48 hours separated each testing day. The order of
doses was counter-balanced. Locomotor activity was assessed as described above.
There was no evidence for locomotor sensitization when the order of testing was
examined as a factor using analysis of variance (ANOVA; data not presented).
Experiment 2: Cocaine-induced Locomotor Activity after a Brief
Period of Habituation
To allow comparison to the results of previously reported locomotor studies in
DAT KO mice that have used different periods of pre-injection habituation [10–
13], locomotor activity was also assessed in all 9 genotypes of DAT/5-HT1B double
KO mice (N58–13 per genotype) after 30 minutes of habituation to the
locomotor test chambers, using a within-subjects design after injections with 0
(saline vehicle) or 20 mg/kg s.c. cocaine. At least 48 hours separated each testing
day and the dose order was counter-balanced.
Experiment 3: Effects of the 5-HT antagonist SB224289 on
locomotor activity in DAT KO and WT mice
Locomotor activity was assessed in DAT 2/2 and wildtype, DAT +/+ littermates
(n510 mice per genotype) as previously described. Mice were injected with the 5-
HT1B antagonist SB224289 (0, 5, 10 or 20 mg/kg i.p.) prior to placement in
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locomotor activity chambers for 1 hour. A within-subjects design was used, at
least 48 hours separated each testing day and the dose order was counter-
balanced.
Statistics
Statistical comparisons were made with ANOVA followed by Scheffe’s post hoc
comparisons using Statview (SAS). Data are presented as mean ¡ SEM for each
experimental group. In Experiment 1 there were substantial differences in basal
activity across genotypes observed during the long habituation period. This
difference in activity between genotypes did not equalize even by the end of this
extended period of habituation. The habituation sessions were compared to each
other to determine if the patterns observed in the first exposure were maintained
or if there were differences in habituation resulting from DAT GENOTYPE or 5-
HT1B GENOTYPE or any other factors. Because the activity of the groups was not
equalized by the end of the habituation period, cocaine-induced locomotion was
analyzed in terms of difference scores of the summed activity over the two hours
of testing post-cocaine minus the summed activity over the 2 hours of baseline
activity immediately prior to cocaine injection. Since the short habituation data in
Experiment 2 did not allow this correction, the difference in locomotor activity
after saline injection was compared to locomotor activity after cocaine injection in
the initial ANOVA, and then the time-course of cocaine and saline responses was
examined in separate ANOVA for each genotype. In ANOVA, the between-
subjects factors used were DAT GENOTYPE and 5-HT1B GENOTYPE, along with
the within-subjects factors TIME (for baseline locomotion), habituation SESSION
(for pre-cocaine habituation sessions) and DOSE of cocaine or SB 224289, where
appropriate.
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